A groundbreaking new study has shown that a treatment used to tackle acute COVID-19 infection also works wonders on long COVID sufferers. The findings of the study, which looked at the effectiveness of monoclonal antibodies, could bring new hope for millions of Americans struggling with long COVID.
Published in the prestigious American Journal of Emergency Medicine, the study revealed that three patients in Florida experienced complete recoveries from long COVID after being administered the monoclonal antibody cocktail, casirivimab/imdevimab (Regeneron).
Speaking on the findings, study coauthor Paul Pepe, MD, MPH, a professor at the University of Texas Health Sciences Center, said “We were struck by how rapid and complete the remissions were. No matter how long the patients were sick for — whether it was 5, 8, or 18 months — within 5 days, they appeared to be completely cured.”
These patients had initially contracted COVID-19 early in the pandemic and were later given Regeneron, either following a reinfection or as a preventative measure, at state-run COVID clinics in Florida.
The groundbreaking study involved collecting detailed medical histories and closely monitoring symptoms. According to Pepe, the results were astonishing. “In each case, the infusions were given to help prevent their long COVID from worsening,” he explained.
The patients’ loved ones corroborated the improvements, according to the researchers.
One of the patients, who wished to remain anonymous, described the debilitating symptoms she had been facing: extreme fatigue, chest pain, and shortness of breath. However, after just 4 days post-treatment, her symptoms began to vanish, providing relief and allowing her to enjoy a better quality of life.
To learn more about this groundbreaking research, click on the link below.
